Overview

Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy (PEVENAZA)

Status:
Active, not recruiting

Trial end date:
2024-03-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether the combination of pevonedistat + venetoclax + azacitidine improves event-free survival (EFS) compared with venetoclax + azacitidine in patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Takeda

Treatments:

Azacitidine
Pevonedistat
Venetoclax